Table 3: Response to tyrisine kinase (i.e. imatinib mesylate) in patients with myeloid neoplasms associated with ETV6-PDGFRB rearrangement.
Study | Male/Female | ETV6-PDGFRB patients/Other PDGFR rearrangements | Tyrosine kinase (i.e. imatinib mesylate) Dosage regimen | Response to treatment |
---|---|---|---|---|
Apperley, et al. [17] | 4/0 | 4/0 | From 400 to 800 mg/daily | No residual disease at 9 to 12 months after the initiation of the treatment |
David, et al. [36] | 10/2 | 8/4 | From 200 to 800 mg/daily | Hematological response: 49 months (19-60 months)
Cytogenetic response: 47 months (16-59 months) 10 patients were still alive at the time of publication (including all ETV6-PDGFRB patients) |
Arefi, et al. [8] | 8/2 | 2/8 | 400 mg/daily | 7 patients achived complete cytologic and hematological reponse including both ETV6-PDGFRB patients - median follow-up = 19 months |